Abstract
BackgroundBowel cancer screening increases early stage disease detection and reduces cancer-specific mortality. We assessed the relationship between co-morbidity, screen-detection and survival in colorectal cancer.MethodsA retrospective, observational cohort study compared screen-detected (SD) and non-screen-detected (NSD) patients undergoing potentially curative resection (April 2009–March 2011). Co-morbidity was quantified using ASA, Lee and Charlson Indices. Systemic inflammatory response was measured using the neutrophil lymphocyte ratio (NLR). Covariables were compared using crosstabulation and the χ2 test for linear trend. Survival was analysed using Cox Regression.ResultsOf 770 patients, 331 had SD- and 439 NSD-disease. A lower proportion of SD patients had a high ASA (≥3) compared to NSD (27.2% vs 37.3%; p = 0.007). There was no significant difference in the proportion of patients with a high (≥2) Lee Index (16.3% SD vs 21.9% NSD; p = 0.054) or high (≥3) Charlson Index (22.7% SD vs 26.9% NSD; p = 0.181). On univariate analysis, NSD (HR 2.182 (1.594–2.989;p < 0.001)), emergency presentation (HR 3.390 (2.401–4.788; p < 0.001)), advanced UICC-TNM (III or IV) (p < 0.001), high ASA (≥3) (HR 1.857 (1.362–2.532; p < 0.001)), high Charlson Index (≥3) (HR 1.800 (1.333–2.432; p < 0.001)) and high (≥3) NLR (HR 1.825 (1.363–2.442; p < 0.001)) were associated with poorer overall survival (OS). NSD predicted poorer cancer-specific survival (CSS) (HR 2.763 (1.776–4.298; p < 0.001)). On multivariate analysis, NSD retained significance as an independent predictor of poorer OS (HR 1.796 (1.224–2.635; p = 0.003)) and CSS (HR 1.924 (1.193–3.102; p = 0.007)).ConclusionsPatients with SD cancers have significantly lower ASA scores. After adjusting for ASA, co-morbidity and a broad range of covariables, SD patients retain significantly better OS and CSS.
Highlights
Colorectal cancer is the fourth most common cancer in the UK, with approximately 41,000 new cases and 16,000 deaths each year [1]
The aim of the present study was to assess the relationship between co-morbidity, screen-detection and overall survival in patients with colorectal cancer
To identify patients with non-screen-detected colorectal cancers diagnosed during the same time period and within the same health board, the West of Scotland Colorectal Cancer Managed Clinical Network (MCN) dataset and the Scottish Cancer Registry (SMR06) datasets were cross-referenced
Summary
Colorectal cancer is the fourth most common cancer in the UK, with approximately 41,000 new cases and 16,000 deaths each year [1]. Bowel cancer screening increases early stage disease detection and reduces cancer-specific mortality. We assessed the relationship between co-morbidity, screen-detection and survival in colorectal cancer. A lower proportion of SD patients had a high ASA (C3) compared to NSD (27.2% vs 37.3%; p = 0.007). NSD (HR 2.182 (1.594–2.989;p \ 0.001)), emergency presentation (HR 3.390 (2.401–4.788; p \ 0.001)), advanced UICC-TNM (III or IV) (p \ 0.001), high ASA (C3) (HR 1.857 (1.362–2.532; p \ 0.001)), high Charlson Index (C3) (HR 1.800 (1.333–2.432; p \ 0.001)) and high (C3) NLR (HR 1.825 (1.363–2.442; p \ 0.001)) were associated with poorer overall survival (OS). After adjusting for ASA, co-morbidity and a broad range of covariables, SD patients retain significantly better OS and CSS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
